(Dimethylamino) acetaldehyde Diethyl Acetal CAS 3616-56-6 Pite > 99.0% (GC) Afatinib Dimaleate Faktori Entèmedyè
Ruifu Chimik Pwovizyon pou Entèmedyè nan Afatinib
Afatinib CAS 439081-18-2
Afatinib Dimaleate CAS 850140-73-7
(S)-(+)-3-Hydroxytetrahydrofuran CAS 86087-23-2
(Dimethylamino) acetaldehyde Diethyl Acetal CAS 3616-56-6
trans-4-Dimethylaminocrotonic Asid Hydrochloride CAS 848133-35-7
Diethylphosphonoacetic Asid CAS 3095-95-2
7-Fluoro-6-Nitroquinazolin-4(1H)-yon sèl CAS 162012-69-3
7-Chloro-6-Nitro-4-Hydroxyquinazoline CAS 53449-14-2
N-(3-Chloro-4-Fluorophenyl)-7-Fluoro-6-Nitroquinazolin-4-Amine CAS 162012-67-1
(S)-N4-(3-Chloro-4-Fluorophenyl)-7-((Tetrahydrofuran-3-yl)oxy)quinazoline-4,6-DiamineCAS 314771-76-1
(S)-N-(3-Chloro-4-Fluorophenyl)-6-Nitro-7-((Tetrahydrofuran-3-yl)oxy)quinazolin-4-AmineCAS 314771-88-5
Non Chimik | (Dimethylamino)acetaldehyde Diethyl Acetal |
Sinonim | 2,2-Diethoxy-N,N-Dimethylethylamine;N-(2,2-dietoksietil) dimetilamin;2,2-Diethoxy-N,N-Dimethylethan-1-Amine |
Nimewo CAS | 3616-56-6 |
Nimewo CAT | RF-PI2031 |
Estati Stock | Nan Stock, Pwodiksyon Echèl Jiska Tòn |
Fòmil molekilè | C8H19NO2 |
Pwa molekilè | 161.25 |
Sansiblite | Imidite sansib |
Pwen bouyi | 60℃/5 mmHg |
Flash Point | 45℃ |
Mak | Ruifu Chimik |
Atik | Espesifikasyon |
Aparans | Likid san koulè klè |
Pite / Metòd analiz | >99.0% (GC) |
Endèks refraktif N20/D | 1.410 ~ 1.414 |
Gravite espesifik (20/20 ℃) | 0.865 ~ 0.870 |
Spectre proton RMN | Konfòm ak estrikti |
Enpurte total | <1.00% |
Metal lou (tankou Pb) | ≤20ppm |
Tès Creole | Enterprise Standard |
Itilizasyon | Entèmedyè famasetik;Afatinib Dimaleate;Sumatriptan |
Pake: Fliyò boutèy, 25kg/tanbou, oswa selon kondisyon kliyan an
Kondisyon Depo:Sere nan resipyan ki fèmen nan yon kote ki fre ak sèk;Pwoteje kont limyè ak imidite
(Dimethylamino)acetaldehyde Diethyl Acetal (CAS: 3616-56-6) yo itilize kòm entèmedyè pharmaceutique.(Dimethylamino)acetaldehyde Diethyl Acetal ka itilize nan sentèz Afatinib Dimaleate (CAS: 850140-73-7), Sumatriptan (CAS: 103628-46-2).Afatinib (non komèsyal Gilotrif nan peyi Etazini ak Giotrif an Ewòp, deja Tomtovok ak Tovok) se yon dwòg apwouve nan Etazini, Ewòp, Taiwan, Meksik, Chili ak Japon ak lòt peyi pou tretman premye liy pasyan ki gen diferan. kalite metastatik (EGFR mitasyon pozitif) ki pa ti selil kansè nan poumon (NSCLC), devlope pa Boehringer Ingelheim.Afatinib aji kòm yon inibitè kovalan irevokabl nan reseptè tirozin kinaz epidèm faktè kwasans (EGFR) ak erbB-2 (HER2).Sumatriptan se premye triptan ki te apwouve (1991) pou tretman egi nan maltèt migrèn.Li gen byodisponibilite ki pi ba nan mitan tout triptan akòz lipofilisite li yo.Disponibilite anpil fòm dòz diferan (sa vle di, yon grenn oral, yon piki SC, yon fòmilasyon espre nan nen, ak yon sipozitwa) pèmèt fleksibilite nan tailoringterapi a bezwen pasyan yo endividyèl, kidonk fè sumatriptan yo yon dwòg trè itil pou yon tretman egi nan migrèn. tèt fè mal.Sumatriptan tou gen yon trè fastonset nan aksyon atravè piki SC oswa administrasyon espre nan nen.